AI assistant
Sending…
RLI CORP — Director's Dealing 2022
Feb 10, 2022
30928_dirs_2022-02-10_578bbf33-d6bd-4243-8ca0-283f18c19831.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 5 — Annual Statement of Changes in Beneficial Ownership
Issuer: RLI CORP (RLI)
CIK: 0000084246
Period of Report: 2021-12-31
Reporting Person: Kliethermes Craig W (Director, President & CEO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 52677 | Direct |
| Common Stock | 6419.995 | Indirect |
| Common Stock | 10335.383 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $93.24 | 2028-08-21 | Common Stock (20000) | 20000 | Direct |
| Stock Option | $113.02 | 2029-05-06 | Common Stock (14000) | 14000 | Direct |
| Stock Option | $64.09 | 2024-05-05 | Common Stock (3000) | 3000 | Direct |
| Stock Option | $56.71 | 2025-05-04 | Common Stock (8400) | 8400 | Direct |
| Stock Option | $63.14 | 2026-05-03 | Common Stock (20000) | 20000 | Direct |
| Stock Option | $82.66 | 2027-05-02 | Common Stock (21000) | 21000 | Direct |
Footnotes
F1: Reflects a transfer of 74,847 shares and 82,900 stock options to Mr. Kliethermes' former spouse pursuant to a domestic relations order as to which he no longer claims beneficial ownership.
F2: Ownership reflects dividend reinvestment.
F3: Ownership reflects shares allocated to ESOP participant's account and dividend reinvestment.
F4: Pursuant to option schedule wherein 20% of the aggregate number of shares granted may be exercised commencing one year from grant date and each year thereafter in 20% increments.
More from RLI CORP
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 14
Major Shareholding Notification
2026
Apr 30
Major Shareholding Notification
2026
Apr 29
Regulatory Filings
2026
Apr 28
Interim / Quarterly Report
2026
Apr 24
Regulatory Filings
2026
Apr 22
Regulatory Filings
2026
Mar 27
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 26